Fair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
38.5%/yr
±1.9% · revenue growth to justify current price
FCF-Based Reverse DCF
43.4%/yr
±3.6% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.
Sign in to unlockIDEXX Laboratories, Inc.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
IDXX delivered 10% organic revenue growth in 2025 with 8.1% CAG Diagnostics recurring revenue growth. Operating margins expanded 90bps on comparable basis to 31.4%. Thesis: recurring diagnostics busin...